SMTL ID : 8tui.1

Crystal structure of Fab-Lirilumab bound to KIR2DL3

Coordinates

PDB Format

Method

X-RAY DIFFRACTION 2.75 Å

Oligo State

hetero-1-1-1-mer

Ligands

1 x NAG- NAG- BMA- MAN- NAG- MAN- FUC: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-2)-alpha-D-mannopyranose-(1-6)-[alpha-D-mannopyranose-(1-3)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-[alpha-L-fucopyranose-(1-6)]2-acetamido-2-deoxy-beta-D-glucopyranose

NAG-NAG-BMA-MAN-NAG-MAN-FUC.1: 4 residues within 4Å: Chain C: H.13, I.25, E.54, N.63 2 PLIP interactions: 2 interactions with chain C Hydrophobic interactions: C:H.13, C:I.25

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Lorig-Roach, N. et al., Structural basis for the activity and specificity of the immune checkpoint inhibitor lirilumab. Sci Rep (2024)

Release Date

2023-12-06

Peptides

Lirilumab Fab Heavy Chain: A
Lirilumab Fab Light chain: B
Killer cell immunoglobulin-like receptor 2DL3: C

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
H

B
L

C
A

Lirilumab Fab Heavy Chain

Lirilumab Fab Light chain

Killer cell immunoglobulin-like receptor 2DL3

Related Entries With Identical Sequence